Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

By
Kerri Miller
May 7, 2026
3 min

Conexiant

Overview

The phase 1 DOVETAIL trial demonstrated that vamikibart, an intravitreal anti-IL-6 monoclonal antibody, showed no sustained intraocular pressure elevations or new cataracts, indicating a favorable safety profile. However, it is important to note that the trial was not designed to assess efficacy. Preliminary visual and anatomic outcomes were promising, with significant improvements in best-corrected visual acuity and resolution of intraretinal fluid.

Background

Uveitic macular edema is a significant cause of vision loss, often treated with corticosteroids that carry risks such as cataract formation and elevated intraocular pressure. The DOVETAIL trial aimed to evaluate the safety and tolerability of vamikibart, a novel treatment option that may offer a steroid-sparing alternative. Understanding the safety profile of new therapies is crucial for improving patient outcomes in uveitis management.

Data Highlights

Outcome	Results
Intraocular Pressure Elevation	0% in vamikibart group
Best-Corrected Visual Acuity Improvement	10.7 and 9.0 letter scores in lower dose groups
Complete Resolution of Intraretinal Fluid	80% by week 12
Maintenance of Resolution	67% to 90% at study end

(Note: Results should be interpreted with caution due to the trial's limitations, including the absence of a control group.)

Key Findings

No drug-related serious adverse events reported in the DOVETAIL trial.
One patient experienced worsening uveitis, resolved after 75 days and deemed unrelated to vamikibart.
Improvements in visual acuity were maintained through 36 weeks in lower dose groups.
Over 80% of participants had complete resolution of intraretinal fluid by week 12.
Improvements in anterior chamber cells and vitreous haze suggest broader effects on intraocular inflammation.
Note: The trial's small size and lack of randomization may affect the interpretation of these findings.

Clinical Implications

Vamikibart presents a promising safety profile for treating uveitic macular edema, potentially reducing the risks associated with corticosteroid use. However, clinicians should consider vamikibart as a viable option for patients who require steroid-sparing therapies only after further efficacy data from ongoing trials is available.

Conclusion

The DOVETAIL trial findings suggest that vamikibart may be a safe alternative for managing uveitic macular edema, but these findings are preliminary and warrant further investigation in larger, randomized trials to confirm efficacy.